**Supplementary Data**

**S4 Fig: Subgroup analyses and funnel plots**

***Calcium-channel blockers***

*a) trials reporting “measured and validated” OH outcomes only*

**

*b) trials at low risk of bias*

**

*c) older participants ≥ 65 years*

**

*d) participants with cardiovascular conditions*

******

******

***ACE inhibitors/ARBs***

*a) trials reporting “measured and validated” OH outcomes only*



*b) dose*

*low dose*

**

*high dose*

**

*c) populations at greater risk of OH (excluding healthy volunteers)*

**

*Funnel plot*

**

***SSRIs/serotonin modulators***

*a) trials reporting “measured and validated” OH outcomes only*

**

*b) drug dose*

*Low dose*

**

*High dose*

**

*3) older patients ≥ 65 years*

**

*Funnel plot*

**

***SGLT-2 inhibitors***

*a) trials at low risk of bias (excluding trials with an overall score of “high”).*

**

*b) trials in patients with T2DM*

**

*c) trials in patients with T2DM and cardiovascular disease*

**

*Funnel plot*

**

***Alpha-adreno receptor blockers***

*1) trials reporting “measured and validated” OH outcomes only*



*Funnel plot*

**

***Centrally acting antihypertensives (alpha-agonists)***

**

***Second generation antipsychotics***

*1) trials reporting “measured and validated” OH outcomes only*

******

*b) dose*

*low dose*

**

*high dose*

**

*c) populations with mental health conditions (excluding healthy volunteers)*

**

*Funnel plot*

**

***Beta-blockers***

*a) trials with “measured and validated” OH outcomes*

**

*b) low dose (excluding 1 trial with high dose)*

**

*c) population at higher risk of OH (hypertension; angina; heart failure)*

**

*Funnel plot*

**

*Tricyclic antidepressants (TCAs)*

*Funnel plot*

**